{"gene":"EIF2B5","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1993,"finding":"Glycogen synthase kinase-3 (GSK-3) phosphorylates the epsilon subunit of eIF-2B, and insulin rapidly inactivates GSK-3 (via phosphorylation of GSK-3 itself, reversible by protein phosphatase-2A), thereby modulating eIF-2B activity.","method":"Chromatographic fractionation of CHO cell extracts, kinase assays with GSK-3-specific peptide substrates, immunoblotting with isoform-specific GSK-3 antibodies, phosphatase treatment","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro kinase assay plus immunoblotting; replicated and foundational; consistent with multiple downstream studies","pmids":["8397507"],"is_preprint":false},{"year":1994,"finding":"eIF-2B is the guanine nucleotide exchange factor (GEF) for eIF-2; it promotes release of GDP from inactive eIF-2·GDP complexes to allow formation of active eIF-2·GTP, and this activity is inhibited when the alpha subunit of eIF-2 is phosphorylated. eIF-2B is a heteropentamer (subunits α, β, γ, δ, ε); the ε subunit is the catalytic subunit phosphorylated by protein kinases in liver extracts.","method":"Purification of eIF-2B from rat/bovine liver to >95% homogeneity; guanine nucleotide exchange assays; monoclonal antibody generation; protein kinase assays on individual subunits","journal":"Biochimica et biophysica acta / Biochimie / European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution, biochemical purification, in vitro enzymatic assay; replicated across multiple labs","pmids":["7803480","7893825","8168527"],"is_preprint":false},{"year":1994,"finding":"Phosphorylation of eIF-2α at Ser-51 by eIF-2α kinase (HRI) inhibits eIF-2B guanine nucleotide exchange activity in cell extracts; Ser-48 of eIF-2α also contributes by maintaining high-affinity interaction between phosphorylated eIF-2α and eIF-2B, sequestering eIF-2B in an inactive complex.","method":"Cell extracts from CHO cells overexpressing wild-type or mutant eIF-2α (S48A, S51A); in vitro kinase treatment with purified HRI; GEF activity assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis plus in vitro kinase assay, mechanistic follow-up with multiple mutants","pmids":["8007958"],"is_preprint":false},{"year":1994,"finding":"Overexpression of all five subunits of eIF-2B suppresses the growth-inhibitory and translational effects of eIF-2α hyperphosphorylation in yeast, establishing that phosphorylated eIF-2 acts as a competitive inhibitor of eIF-2B (rather than forming an irreversible inhibitory complex), and that eIF-2·GTP·Met-tRNA ternary complex concentration is the cardinal parameter controlling translation.","method":"Yeast genetic overexpression of eIF-2B subunits (all five), gene dosage experiments, GCN4-lacZ reporter assays, genetic epistasis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with multiple orthogonal readouts; foundational yeast study directly applicable to mammalian eIF2B5 function","pmids":["7565788"],"is_preprint":false},{"year":1994,"finding":"Mutations in the GCD7 (β) and GCD2 (δ) subunits of yeast eIF-2B suppress inhibition by phosphorylated eIF-2α, revealing that these subunits mediate the regulatory interaction between phospho-eIF-2 and eIF-2B without impairing the essential catalytic function, and that the eIF-2B complex can be rendered insensitive to eIF-2α phosphorylation.","method":"Yeast suppressor screen; GCN4-lacZ reporter; in vivo phosphorylation assays; growth assays with activated GCN2c kinase","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with suppressor screen, multiple mutant alleles, replicated in yeast ortholog studies","pmids":["8164676"],"is_preprint":false},{"year":2000,"finding":"The C-terminal domain of eIF2Bε (residues 518–712 in yeast) is required for both catalytic GEF activity and binding to eIF-2; the N-terminal half of eIF2Bε contains an activation domain that responds to complex formation with other eIF2B subunits to enhance the nucleotide exchange rate, but missense mutations in this domain impair complex-stimulated activity without affecting intrinsic exchange activity or eIF2 binding.","method":"Yeast mutagenesis (nonsense, missense, in-frame deletions) of GCD6 (eIF2Bε); in vitro GEF assays with purified proteins; co-immunoprecipitation of subunit interactions","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — systematic mutagenesis combined with in vitro GEF assays and binding assays; comprehensive domain dissection","pmids":["10805739"],"is_preprint":false},{"year":2001,"finding":"DYRK2 and DYRK1A phosphorylate Ser-539 (rat numbering) in eIF2Bε, which is a priming phosphorylation that enables GSK-3 to subsequently phosphorylate the inhibitory Ser-535 site; eIF2Bε is highly phosphorylated at Ser-539 in vivo.","method":"In vitro kinase assays with purified DYRK isoforms, GSK-3, and eIF2Bε peptides/protein; mass spectrometry of phosphorylation sites; in vivo phosphorylation analysis","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of sequential phosphorylation; site-specific identification; confirmed in vivo","pmids":["11311121"],"is_preprint":false},{"year":2002,"finding":"GSK-3 phosphorylates Ser-535 of eIF2Bε in vivo (confirmed by GSK-3 inhibitors LiCl, SB-415286, SB-216763 causing dephosphorylation), but dephosphorylation of Ser-535 alone is insufficient to activate eIF-2B in response to insulin, indicating that additional regulatory inputs are required for eIF2B activation.","method":"Pharmacological GSK-3 inhibitors in CHO cells; phospho-specific antibodies against Ser-535; eIF2B activity assays; phosphoinositide 3-kinase pathway inhibitors","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal pharmacological tools with kinase activity and phosphorylation readouts in the same study","pmids":["12133000"],"is_preprint":false},{"year":1992,"finding":"Agents that disrupt ER Ca2+ homeostasis (thapsigargin, A23187, EGTA, DTT) inhibit translational initiation in GH3 cells concomitantly with ~5-fold increase in eIF-2α phosphorylation and ~50% reduction in eIF-2B activity, establishing that ER stress leads to eIF-2B inhibition via eIF-2α phosphorylation.","method":"Metabolic labeling, isoelectric focusing of eIF-2α, eIF-2B activity assays, acute and chronic drug treatment in intact cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (phosphorylation + activity assays) with functional consequence; foundational ER stress-eIF2B link","pmids":["1512215"],"is_preprint":false},{"year":1996,"finding":"Glucose activates eIF-2B activity in isolated rat pancreatic islets within 15 min via a pathway independent of changes in eIF-2α phosphorylation, indicating a direct regulatory mechanism for eIF-2B activity by glucose metabolism.","method":"Isolated rat islet preparations; guanine nucleotide exchange assays; isoelectric focusing of eIF-2α; non-metabolizable glucose analogue controls","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — biochemical activity assays with appropriate controls demonstrating phosphorylation-independent mechanism","pmids":["8567668"],"is_preprint":false},{"year":2002,"finding":"Sepsis increases GSK-3 activity (reduced Ser-9 phosphorylation of GSK-3β) and augments phosphorylation of eIF2Bε-Ser-535 by >2-fold in rat skeletal muscle, reducing eIF2B activity; TNF-binding protein treatment prevented these changes, implicating TNF as the mediator. This provides the first in vivo demonstration of eIF2Bε phosphorylation changes.","method":"Rat sepsis model; phospho-specific antibodies; eIF2B kinase/phosphatase activity assays; in vivo pharmacological intervention with TNF-binding protein","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — in vivo model with multiple readouts (phosphorylation, kinase activity, pharmacological rescue); first in vivo demonstration","pmids":["12376332"],"is_preprint":false},{"year":2000,"finding":"EGF- and NGF-induced activation of eIF-2B in PC12 cells requires MEK/ERK signaling (blocked by PD98059), and this activation is accompanied by GSK-3 inactivation; however, activation of eIF-2B occurs without detectable change in Ser-535 phosphorylation of eIF2Bε, indicating MEK/ERK-dependent but GSK-3/Ser-535-independent regulatory mechanisms.","method":"PC12 cell pharmacological inhibition (PD98059); eIF-2B activity assays; phospho-specific antibody detection of Ser-535","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological epistasis with activity and phosphorylation readouts; single lab, single study","pmids":["10913625"],"is_preprint":false},{"year":2008,"finding":"Resistance exercise in young men reduces phosphorylation of eIF2Bε at Ser-540 (equivalent to rat Ser-535) in skeletal muscle, consistent with GSK-3 inhibition and eIF-2B activation, linking exercise signaling to eIF2Bε dephosphorylation.","method":"Human skeletal muscle biopsies; phospho-specific immunoblotting; unilateral exercise design with contralateral control","journal":"American journal of physiology. Regulatory, integrative and comparative physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct phosphorylation measurement in vivo in humans; single study, single method for eIF2Bε","pmids":["18565837"],"is_preprint":false},{"year":2005,"finding":"EIF2B5 mutations in VWM patient cells severely compromise the generation of GFAP+ astrocytes from glial progenitors; RNAi targeting of EIF2B5 in normal human glial progenitors phenocopies this defect, establishing a specific cell-autonomous role for eIF2Bε in astrocyte differentiation.","method":"Primary cell culture from VWM patient brain; GFAP immunostaining; siRNA knockdown of EIF2B5 in normal human glial progenitors","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — patient-derived cells plus RNAi knockdown with defined cellular phenotype; two orthogonal approaches","pmids":["15723074"],"is_preprint":false},{"year":2013,"finding":"DYRK2 negatively regulates cardiomyocyte growth by priming GSK-3β-mediated phosphorylation and inhibition of eIF2Bε; DYRK2 overexpression increases p-Ser535-eIF2Bε and reduces cardiomyocyte size, while DYRK2 knockdown decreases p-Ser535-eIF2Bε; constitutively active eIF2Bε-S535A causes cardiac hypertrophy in transgenic mice.","method":"Transgenic mice overexpressing eIF2Bε or eIF2Bε-S535A; adenoviral overexpression of DYRK2 in cardiomyocytes; siRNA knockdown of DYRK2; phospho-specific immunoblotting; cardiac morphometry","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches (transgenic, adenoviral OE, siRNA KD) with defined in vivo and cellular phenotypes","pmids":["24023715"],"is_preprint":false},{"year":2012,"finding":"The pyrophosphorylase-like domain (PLD) and left-handed β-helix domain of eIF2Bε and eIF2Bγ mediate critical inter-subunit interactions required for eIF2B complex formation; no evidence supports the PLD of eIF2Bε contributing to nucleotide exchange activity directly.","method":"Yeast genetic analysis; co-expression and co-precipitation of deletion/domain constructs; predicted structural modeling","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-precipitation plus genetic analysis; single lab study on domain interactions","pmids":["22238343"],"is_preprint":false},{"year":2013,"finding":"The C-terminal domain of human eIF2Bε has GEF activity when expressed and purified from yeast; VWM disease mutations within this domain reduce its GEF activity, confirming that the catalytic domain of eIF2Bε is directly impaired by VWM mutations.","method":"Affinity purification of recombinant human eIF2Bε C-terminal domain from engineered yeast; in vitro GEF assays; comparison with patient lymphocyte-derived eIF2B activity","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of human eIF2Bε GEF activity; first demonstration of human domain activity; validated against patient mutations","pmids":["23335982"],"is_preprint":false},{"year":2016,"finding":"eIF2Bε acts as a downstream effector of the AKT-GSK-3β signaling axis in CNS axon regeneration; inactivation of eIF2Bε reduces GSK-3β and AKT-mediated axon regeneration of retinal ganglion cells after optic nerve injury, while constitutively active eIF2Bε is sufficient to promote axon regeneration independently of mTORC1.","method":"Mouse optic nerve injury model; conditional Pten deletion; genetic epistasis with constitutively active and dominant-negative eIF2Bε constructs; retinal ganglion cell survival and axon counting","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with loss-of-function and gain-of-function in vivo; defined cellular and molecular phenotype","pmids":["26974342"],"is_preprint":false},{"year":2017,"finding":"Under hypoxia, intron retention in EIF2B5 generates a 65 kDa truncated eIF2Bε isoform that acts as a dominant-negative to inhibit global translation; this is mediated by hypoxia-induced SRSF3 binding at the retained intron and increased Ser2-phosphorylated RNA Pol II at this region during cotranscriptional processing.","method":"RNA-seq/exon-level analysis; minigene splicing assays; expression of truncated isoform in cancer cells; polysome profiling; RIP assays for SRSF3; ChIP for phospho-Pol II","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (RNA-seq, RIP, ChIP, functional overexpression) establishing mechanism in a single comprehensive study","pmids":["28961236"],"is_preprint":false},{"year":2010,"finding":"Ectopic expression of eIF2Bε in rat skeletal muscle increases GEF activity in healthy animals and rescues the sepsis-induced deficit in eIF2B GEF activity and muscle protein synthesis, demonstrating that eIF2Bε expression level is rate-limiting and sufficient to correct eIF2B deficits.","method":"In vivo plasmid transfection into tibialis anterior; sepsis rat model; GEF activity assays; protein synthesis measurement by metabolic labeling","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — in vivo gain-of-function with defined biochemical and physiological readout; rescue of disease phenotype","pmids":["20484009"],"is_preprint":false},{"year":2019,"finding":"A point mutation in mouse Eif2b5 (p.Ile98Met) decreases eIF2B guanine nucleotide exchange activity on eIF2, elevates ATF4 (ER stress marker) in brain, causes white matter disruption with oligodendrocyte progenitor clustering, and produces neurological phenotypes including epileptic seizures and infertility, establishing direct links between eIF2Bε GEF function and CNS homeostasis.","method":"Spontaneous mutant mouse characterization; biochemical GEF assay; immunohistochemistry; GFAP and CHOP mRNA expression; behavioral testing","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model with biochemical GEF assay validation and multiple orthogonal phenotypic readouts","pmids":["31587290"],"is_preprint":false},{"year":2020,"finding":"In zebrafish VWM models, intron 12 retention in eif2b5 leads to a truncated eif2b5 transcript; expression of this truncated eif2b5 in wild-type larvae activates the integrated stress response (ISR) and impairs motor behavior, suggesting a feed-forward gain-of-function mechanism contributing to VWM pathophysiology.","method":"Zebrafish eif2b5 mutant generation; RNA analysis; rescue by human EIF2B2 expression; motor behavioral assays; ISR marker analysis","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2-3 — zebrafish model with functional rescue and gain-of-function expression; single study","pmids":["33300869"],"is_preprint":false},{"year":2021,"finding":"eIF2Bε promotes Wnt-mediated clonogenicity and global translational capacity in intestinal epithelial cells; eIF2BεArg191His (reduced GEF activity) mice show impaired crypt formation, reduced stemness marker expression, and defective Paneth cell granule formation; eIF2Bε is essential for Wnt hyperactivation-associated translational increase in organoids.","method":"eIF2Bε Arg191His knock-in mice; intestinal organoid culture; GSK3β inhibitor Wnt activation; stemness marker expression; protein synthesis assays","journal":"Stem cell research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knock-in model with multiple cellular readouts; single lab","pmids":["34399164"],"is_preprint":false},{"year":2025,"finding":"Cell-type-specific Eif2b5 conditional mouse models reveal that oligodendrocyte-specific Eif2b5 mutation is the primary driver of ataxia and myelination defects in VWM, while astrocyte-specific Eif2b5 mutation drives intramyelinic vacuolization and ATF4-related gene expression with only mild motor phenotype; neuronal Eif2b5 mutation produces very mild phenotype.","method":"Cell-type-specific conditional Eif2b5 mouse lines (astrocyte, oligodendrocyte, neuron Cre drivers); motor behavioral testing; neuropathology; IHC for myelin proteins, astrocyte/oligodendrocyte markers; ISR/ATF4 gene expression analysis","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 2 — rigorous genetic epistasis with three distinct conditional lines and multiple orthogonal readouts establishing cell-type-specific contributions","pmids":["40326783"],"is_preprint":false},{"year":1987,"finding":"Phosphorylation of eIF-2α prevents eIF-2B-mediated dissociation of eIF-2·GDP from the 60S ribosomal subunit of complete initiation complexes; exogenous eIF-2B restores this function in inhibited lysates, shifting complexes from half-mers back to actively elongating polysomes.","method":"Rabbit reticulocyte lysate; polysome fractionation; sucrose gradient sedimentation; addition of purified exogenous eIF-2B; Met-tRNA binding assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 — biochemical reconstitution in lysate with defined functional readouts; single study","pmids":["3646234"],"is_preprint":false},{"year":1991,"finding":"Purified eIF-2B requires Met-tRNA(fMet) to efficiently exchange GDP for GTP on eIF-2 under physiological conditions; tRNA(fMet) alone is ineffective, indicating that efficient recycling of eIF-2·GDP to eIF-2·GTP in vivo requires formation of the ternary Met-tRNA(fMet)·eIF-2·GTP complex to stabilize the product.","method":"In vitro GEF assays with purified eIF-2B, eIF-2, and tRNA components; comparison of GDP vs GTP exchange rates with/without Met-tRNA","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro reconstitution with purified components; mechanistic insight; single study","pmids":["1764100"],"is_preprint":false},{"year":2008,"finding":"A splice site mutation in EIF2B5 exon 6 causes exon skipping, deleting part of the non-catalytic N-terminal domain of eIF2Bε; the truncated protein is undetectable, and eIF2B GEF activity is severely decreased, demonstrating that the non-catalytic domain of eIF2Bε is required for complex formation and activity.","method":"RT-PCR analysis of patient lymphoblastoid cell RNA; GEF activity assay in patient cells; protein expression analysis","journal":"Annals of human genetics","confidence":"Medium","confidence_rationale":"Tier 2-3 — patient-derived cell biochemistry with GEF assay; single study","pmids":["18294360"],"is_preprint":false},{"year":2022,"finding":"LncRNA KCNQ1OT1 recruits DNA methyltransferases (DNMT1, DNMT3A, DNMT3B) to the EIF2B5 promoter, increasing its methylation and suppressing EIF2B5 expression in ovarian cancer cells; EIF2B5 silencing rescues the anti-tumor effects of KCNQ1OT1 depletion.","method":"MS-PCR for EIF2B5 promoter methylation; RIP and ChIP assays for DNMT binding; dual luciferase reporter assay; siRNA knockdown rescue experiments","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — RIP, ChIP, and methylation assays; functional rescue; single lab study","pmids":["36100884"],"is_preprint":false},{"year":2025,"finding":"EIF2B5 directly interacts with ribosomal protein RPL6 (identified by mass spectrometry and co-immunoprecipitation) in hepatocellular carcinoma cells; EIF2B5 overexpression promotes RPL6 expression and activates the PI3K/AKT/mTOR pathway.","method":"Mass spectrometry after immunoprecipitation; co-IP validation; Western blotting; siRNA knockdown; mouse ectopic tumor assay","journal":"Cellular signalling","confidence":"Low","confidence_rationale":"Tier 3 — single Co-IP/MS identification in cancer context; no in vitro reconstitution or mechanistic dissection","pmids":["40246131"],"is_preprint":false}],"current_model":"EIF2B5 (eIF2Bε) is the catalytic epsilon subunit of the heteropentameric guanine nucleotide exchange factor eIF2B, whose C-terminal domain mediates GDP-to-GTP exchange on eIF2, enabling formation of the eIF2·GTP·Met-tRNA ternary complex required for translation initiation; eIF2Bε activity is negatively regulated by sequential phosphorylation—first by DYRK1A/2 at Ser-539 (priming), then by GSK-3β at Ser-535 (inhibitory)—while phosphorylation of eIF-2α at Ser-51 by stress kinases (HRI, PKR, GCN2, PERK) causes phospho-eIF-2 to sequester and inhibit eIF2B; the N-terminal domain of eIF2Bε serves as an activation domain stimulated by assembly with the other four eIF2B subunits; insulin and growth factors relieve GSK-3β-mediated inhibition via PI3K/AKT, and MEK/ERK signaling provides additional phosphorylation-independent activation inputs; in the CNS, eIF2Bε dysfunction (as in VWM disease mutations) primarily compromises oligodendrocyte maturation and astrocyte function, disrupts the integrated stress response, and impairs white matter homeostasis."},"narrative":{"teleology":[{"year":1987,"claim":"Establishing that eIF-2B is the critical factor that reverses phospho-eIF2α-mediated translational inhibition by recycling eIF-2·GDP on ribosomes answered the question of how translational repression by eIF-2α kinases is mechanistically implemented.","evidence":"Rabbit reticulocyte lysate polysome fractionation with exogenous eIF-2B addition","pmids":["3646234"],"confidence":"Medium","gaps":["Single reconstitution system (reticulocyte lysate); subunit composition of active eIF-2B not determined","Mechanism of phospho-eIF2α-mediated sequestration not resolved"]},{"year":1992,"claim":"Demonstrating that ER stress agents increase eIF-2α phosphorylation and reduce eIF-2B activity in intact cells established the first link between organellar stress and eIF-2B-dependent translational control.","evidence":"GH3 cell ER stress (thapsigargin/DTT); isoelectric focusing of eIF-2α; eIF-2B activity assays","pmids":["1512215"],"confidence":"High","gaps":["Identity of the ER stress kinase (later identified as PERK) unknown at this time","Whether eIF-2B subunit composition changes under stress not tested"]},{"year":1993,"claim":"Identifying GSK-3 as the kinase that phosphorylates eIF2Bε and showing insulin inactivates GSK-3 revealed a direct signaling axis from growth factors to translational control via eIF2B.","evidence":"Chromatographic fractionation of CHO cell extracts; kinase assays; GSK-3 isoform-specific immunoblotting","pmids":["8397507"],"confidence":"High","gaps":["Exact phosphorylation site on eIF2Bε not yet identified","Whether GSK-3 requires a priming kinase not yet known"]},{"year":1994,"claim":"Biochemical purification confirmed eIF-2B as a heteropentamer whose ε subunit is the catalytic component, while genetic epistasis in yeast showed phospho-eIF2α acts as a competitive inhibitor (not an irreversible poison) and that the β/δ subunits mediate the regulatory response to phospho-eIF2α.","evidence":"Purification from rat/bovine liver with GEF assays; yeast overexpression/suppressor genetics with GCN4-lacZ reporters; CHO cell eIF-2α mutagenesis with HRI kinase","pmids":["7803480","8168527","7565788","8164676","8007958"],"confidence":"High","gaps":["No structural information on the pentamer","How ε cooperates with the regulatory subcomplexes not resolved at the protein level"]},{"year":1996,"claim":"Glucose-stimulated eIF-2B activation in pancreatic islets independent of eIF-2α phosphorylation demonstrated that eIF2B activity is regulated by nutrient signals through mechanisms beyond the canonical phospho-eIF2α pathway.","evidence":"Isolated rat pancreatic islets; GEF assays; isoelectric focusing of eIF-2α","pmids":["8567668"],"confidence":"High","gaps":["Molecular target on eIF2B for glucose signal unknown","Whether eIF2Bε phosphorylation changes were not tested"]},{"year":2000,"claim":"Systematic mutagenesis of yeast eIF2Bε mapped catalytic GEF activity and eIF2 binding to the C-terminal domain and identified a distinct N-terminal activation domain responsive to holoenzyme assembly, establishing a two-domain architecture for eIF2Bε function.","evidence":"Yeast GCD6 mutagenesis (nonsense, missense, deletions); in vitro GEF assays; co-immunoprecipitation","pmids":["10805739"],"confidence":"High","gaps":["No atomic-resolution structure of either domain","How N-terminal domain senses assembly not mechanistically resolved"]},{"year":2000,"claim":"EGF/NGF activation of eIF-2B via MEK/ERK without changes in Ser-535 phosphorylation revealed a phosphorylation-independent regulatory input, indicating multiple convergent pathways control eIF2Bε.","evidence":"PC12 cell pharmacological inhibition (PD98059); eIF-2B activity assays; phospho-Ser535 immunoblotting","pmids":["10913625"],"confidence":"Medium","gaps":["Target of MEK/ERK on eIF2B not identified","Single cell type and single lab","Whether a distinct phosphorylation site is involved not excluded"]},{"year":2001,"claim":"Identification of DYRK1A/2 as the priming kinases for Ser-539 that enables GSK-3β to phosphorylate Ser-535 completed the sequential phosphorylation mechanism governing eIF2Bε inhibition.","evidence":"In vitro kinase assays with purified DYRKs, GSK-3, eIF2Bε peptides; mass spectrometry; in vivo phosphorylation analysis","pmids":["11311121"],"confidence":"High","gaps":["Whether DYRK phosphorylation is itself regulated by signaling pathways not determined","Phosphatase(s) that dephosphorylate these sites not identified"]},{"year":2002,"claim":"Pharmacological GSK-3 inhibition confirmed in vivo Ser-535 phosphorylation but showed it was insufficient for insulin-mediated eIF2B activation, proving that additional regulatory inputs exist beyond the GSK-3-Ser535 axis.","evidence":"CHO cells treated with GSK-3 inhibitors (LiCl, SB-415286, SB-216763); phospho-specific antibodies; eIF2B activity assays","pmids":["12133000"],"confidence":"High","gaps":["Identity of the additional regulatory input(s) unknown","Whether they converge on eIF2Bε or other subunits not resolved"]},{"year":2002,"claim":"The first in vivo demonstration that sepsis increases eIF2Bε-Ser535 phosphorylation via TNF-mediated GSK-3 activation in skeletal muscle established pathological relevance of eIF2Bε phosphoregulation.","evidence":"Rat sepsis model; phospho-specific antibodies; eIF2B activity assays; TNF-binding protein rescue","pmids":["12376332"],"confidence":"High","gaps":["Whether TNF acts directly on muscle GSK-3 or via intermediary signaling not resolved","Contribution of eIF-2α phosphorylation in sepsis not fully dissected"]},{"year":2005,"claim":"Demonstrating that VWM patient-derived cells and EIF2B5-knockdown normal progenitors both fail to generate GFAP+ astrocytes established a cell-autonomous role for eIF2Bε in glial differentiation and connected EIF2B5 mutations to VWM disease pathology.","evidence":"Primary cultures from VWM patient brain; GFAP immunostaining; siRNA knockdown of EIF2B5 in normal human glial progenitors","pmids":["15723074"],"confidence":"High","gaps":["Molecular mechanism linking reduced GEF activity to astrocyte differentiation not identified","Oligodendrocyte contribution not examined in this study"]},{"year":2010,"claim":"Ectopic expression of eIF2Bε in rat skeletal muscle rescued sepsis-induced eIF2B GEF deficits and protein synthesis, showing that eIF2Bε expression level is rate-limiting for translation in catabolic states.","evidence":"In vivo plasmid transfection into rat tibialis anterior; sepsis model; GEF assays; metabolic labeling","pmids":["20484009"],"confidence":"High","gaps":["Whether eIF2Bε stoichiometry with other subunits is maintained during overexpression not determined","Long-term therapeutic potential not assessed"]},{"year":2012,"claim":"Mapping the pyrophosphorylase-like and left-handed β-helix domains as mediating eIF2Bε–eIF2Bγ inter-subunit contacts clarified the structural basis for holoenzyme assembly, distinct from the C-terminal catalytic domain.","evidence":"Yeast genetic analysis; co-expression/co-precipitation of domain constructs","pmids":["22238343"],"confidence":"Medium","gaps":["No high-resolution structure available at this time","Whether these domains contribute to regulation not tested","Single lab study"]},{"year":2013,"claim":"Purified human eIF2Bε C-terminal domain demonstrated GEF activity that was reduced by VWM mutations, directly linking patient genotypes to catalytic impairment; concurrently, DYRK2 was shown to regulate cardiomyocyte size through the DYRK2→GSK-3β→eIF2Bε-Ser535 axis, extending eIF2Bε phosphoregulation to cardiac hypertrophy.","evidence":"Recombinant human eIF2Bε catalytic domain purified from yeast with in vitro GEF assays; transgenic mice with eIF2Bε-S535A; adenoviral DYRK2 overexpression/knockdown in cardiomyocytes","pmids":["23335982","24023715"],"confidence":"High","gaps":["Full holoenzyme reconstitution with VWM mutant subunits not achieved","Whether cardiac hypertrophy phenotype involves ISR activation not tested"]},{"year":2016,"claim":"Constitutively active eIF2Bε promoted CNS axon regeneration downstream of AKT-GSK-3β and independently of mTORC1, revealing a new biological role for eIF2B-dependent translation in neural repair.","evidence":"Mouse optic nerve injury model; conditional Pten deletion with constitutively active or dominant-negative eIF2Bε constructs; axon counting","pmids":["26974342"],"confidence":"High","gaps":["Which mRNAs are translationally upregulated by eIF2Bε in regenerating axons not identified","Whether endogenous eIF2Bε is rate-limiting in the regeneration context not tested"]},{"year":2017,"claim":"Hypoxia-induced intron retention in EIF2B5 produces a dominant-negative truncated isoform that inhibits global translation, revealing a post-transcriptional layer of eIF2Bε regulation involving SRSF3-mediated cotranscriptional splicing.","evidence":"RNA-seq; minigene splicing assays; polysome profiling; RIP for SRSF3; ChIP for phospho-Pol II in cancer cells","pmids":["28961236"],"confidence":"High","gaps":["In vivo physiological relevance of intron retention beyond cancer cell lines not established","Whether this mechanism operates in normal tissue hypoxia (e.g., embryonic development) unknown"]},{"year":2019,"claim":"A spontaneous Eif2b5 point mutation in mice directly linked reduced GEF activity to white matter disruption, ATF4 elevation, epileptic seizures, and oligodendrocyte progenitor clustering, providing the first single-gene mouse model recapitulating VWM-like neuropathology.","evidence":"Spontaneous mouse mutant; biochemical GEF assay; immunohistochemistry; behavioral testing","pmids":["31587290"],"confidence":"High","gaps":["Whether ATF4 elevation is cause or consequence of pathology not resolved","Mechanism of oligodendrocyte progenitor clustering unknown"]},{"year":2021,"claim":"eIF2Bε GEF activity was shown to be required for Wnt-mediated intestinal stem cell clonogenicity and Paneth cell maturation, broadening eIF2Bε function beyond the CNS to epithelial homeostasis.","evidence":"eIF2Bε-R191H knock-in mice; intestinal organoid culture; Wnt activation by GSK3β inhibitor; stemness markers","pmids":["34399164"],"confidence":"Medium","gaps":["Whether the phenotype is specific to eIF2Bε or general to eIF2B holoenzyme insufficiency not distinguished","Translational targets downstream of Wnt-eIF2B axis not identified","Single lab study"]},{"year":2025,"claim":"Cell-type-specific conditional Eif2b5 mutagenesis resolved a longstanding question by showing that oligodendrocyte-intrinsic eIF2Bε dysfunction is the primary driver of VWM motor phenotype and myelination defects, while astrocyte-intrinsic dysfunction drives vacuolization and ISR activation.","evidence":"Three conditional Eif2b5 mouse lines (oligodendrocyte, astrocyte, neuron Cre); motor behavior; neuropathology; ISR gene expression","pmids":["40326783"],"confidence":"High","gaps":["Molecular mechanism by which reduced GEF activity specifically impairs oligodendrocyte maturation unknown","Whether therapeutic GEF restoration in specific cell types is sufficient for rescue not tested"]},{"year":null,"claim":"Major open questions include: which specific mRNAs are translationally controlled by eIF2Bε activity changes in disease-relevant cell types; what phosphatases reverse Ser-535/Ser-539 phosphorylation; and what the complete structural basis is for VWM mutation-induced GEF impairment in the human holoenzyme context.","evidence":"","pmids":[],"confidence":"High","gaps":["No translatome profiling of eIF2Bε-mutant cells in disease-relevant lineages","Phosphatase(s) acting on eIF2Bε not identified","Full structural impact of VWM mutations in assembled human decamer not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,5,6,16]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,5]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,3,5,16,24,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,7,11,17]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[18]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2,8,20]}],"complexes":["eIF2B"],"partners":["EIF2S1","EIF2B1","EIF2B2","EIF2B3","EIF2B4","GSK3B","DYRK2","DYRK1A"],"other_free_text":[]},"mechanistic_narrative":"EIF2B5 encodes the catalytic epsilon subunit of the heteropentameric guanine nucleotide exchange factor eIF2B, which recycles eIF2·GDP to eIF2·GTP to enable formation of the eIF2·GTP·Met-tRNAi ternary complex essential for translation initiation [PMID:7803480, PMID:8168527]. The C-terminal domain of eIF2Bε harbors intrinsic GEF activity and binds eIF2, while an N-terminal activation domain amplifies exchange activity upon assembly with the other four eIF2B subunits [PMID:10805739, PMID:23335982]. eIF2Bε is negatively regulated by sequential phosphorylation—DYRK1A/2 primes Ser-539, enabling GSK-3β to phosphorylate the inhibitory Ser-535 site—and is further inhibited when stress-kinase-phosphorylated eIF2α sequesters the holoenzyme; insulin/PI3K/AKT signaling relieves GSK-3β-mediated inhibition, while MEK/ERK provides a phosphorylation-independent activation input [PMID:8397507, PMID:11311121, PMID:12133000, PMID:10913625]. Biallelic EIF2B5 mutations cause vanishing white matter disease (VWM/CACH), with oligodendrocyte-specific loss of eIF2Bε GEF activity being the primary driver of myelination defects and ataxia, while astrocyte-specific dysfunction contributes to vacuolization and integrated stress response dysregulation [PMID:15723074, PMID:31587290, PMID:40326783]."},"prefetch_data":{"uniprot":{"accession":"Q13144","full_name":"Translation initiation factor eIF2B subunit epsilon","aliases":["eIF2B GDP-GTP exchange factor subunit epsilon"],"length_aa":721,"mass_kda":80.4,"function":"Acts as a component of the translation initiation factor 2B (eIF2B) complex, which catalyzes the exchange of GDP for GTP on eukaryotic initiation factor 2 (eIF2) gamma subunit (PubMed:25858979, PubMed:27023709, PubMed:31048492). Its guanine nucleotide exchange factor activity is repressed when bound to eIF2 complex phosphorylated on the alpha subunit, thereby limiting the amount of methionyl-initiator methionine tRNA available to the ribosome and consequently global translation is repressed (PubMed:25858979, PubMed:31048492)","subcellular_location":"Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/Q13144/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/EIF2B5","classification":"Common Essential","n_dependent_lines":1171,"n_total_lines":1208,"dependency_fraction":0.9693708609271523},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"EIF2S3","stoichiometry":0.2},{"gene":"RPS16","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/EIF2B5","total_profiled":1310},"omim":[{"mim_id":"620315","title":"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER 5; VWM5","url":"https://www.omim.org/entry/620315"},{"mim_id":"620314","title":"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER 4; VWM4","url":"https://www.omim.org/entry/620314"},{"mim_id":"620313","title":"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER 3; VWM3","url":"https://www.omim.org/entry/620313"},{"mim_id":"620312","title":"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER 2; VWM2","url":"https://www.omim.org/entry/620312"},{"mim_id":"606687","title":"EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, SUBUNIT 4; EIF2B4","url":"https://www.omim.org/entry/606687"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/EIF2B5"},"hgnc":{"alias_symbol":["EIF2Bepsilon","EIF-2B"],"prev_symbol":[]},"alphafold":{"accession":"Q13144","domains":[{"cath_id":"3.90.550.10","chopping":"45-300","consensus_level":"medium","plddt":88.3086,"start":45,"end":300},{"cath_id":"2.160.10.10","chopping":"332-455_487-516","consensus_level":"high","plddt":85.2209,"start":332,"end":516},{"cath_id":"1.25.40.180","chopping":"550-721","consensus_level":"high","plddt":82.5425,"start":550,"end":721}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13144","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13144-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13144-F1-predicted_aligned_error_v6.png","plddt_mean":78.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EIF2B5","jax_strain_url":"https://www.jax.org/strain/search?query=EIF2B5"},"sequence":{"accession":"Q13144","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13144.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13144/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13144"}},"corpus_meta":[{"pmid":"8397507","id":"PMC_8397507","title":"Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B.","date":"1993","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8397507","citation_count":349,"is_preprint":false},{"pmid":"11311121","id":"PMC_11311121","title":"The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase.","date":"2001","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11311121","citation_count":268,"is_preprint":false},{"pmid":"1512215","id":"PMC_1512215","title":"Phosphorylation of eukaryotic initiation factor (eIF) 2 alpha and inhibition of eIF-2B in GH3 pituitary cells by perturbants of early protein processing that induce GRP78.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1512215","citation_count":116,"is_preprint":false},{"pmid":"7565788","id":"PMC_7565788","title":"Modulation of tRNA(iMet), eIF-2, and eIF-2B expression shows that GCN4 translation is inversely coupled to the level of eIF-2.GTP.Met-tRNA(iMet) ternary complexes.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7565788","citation_count":112,"is_preprint":false},{"pmid":"15723074","id":"PMC_15723074","title":"EIF2B5 mutations compromise GFAP+ astrocyte generation in vanishing white matter leukodystrophy.","date":"2005","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15723074","citation_count":109,"is_preprint":false},{"pmid":"12325082","id":"PMC_12325082","title":"Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus.","date":"2002","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12325082","citation_count":104,"is_preprint":false},{"pmid":"7893825","id":"PMC_7893825","title":"The guanine nucleotide-exchange factor, eIF-2B.","date":"1994","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/7893825","citation_count":89,"is_preprint":false},{"pmid":"10805739","id":"PMC_10805739","title":"Identification of domains and residues within the epsilon subunit of eukaryotic translation initiation factor 2B (eIF2Bepsilon) required for guanine nucleotide exchange reveals a novel activation function promoted by eIF2B complex formation.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10805739","citation_count":84,"is_preprint":false},{"pmid":"26974342","id":"PMC_26974342","title":"GSK3β regulates AKT-induced central nervous system axon regeneration via an eIF2Bε-dependent, mTORC1-independent pathway.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/26974342","citation_count":74,"is_preprint":false},{"pmid":"8567668","id":"PMC_8567668","title":"Glucose stimulates the activity of the guanine nucleotide-exchange factor eIF-2B in isolated rat islets of Langerhans.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8567668","citation_count":73,"is_preprint":false},{"pmid":"18565837","id":"PMC_18565837","title":"Resistance exercise decreases eIF2Bepsilon phosphorylation and potentiates the feeding-induced stimulation of p70S6K1 and rpS6 in young men.","date":"2008","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18565837","citation_count":63,"is_preprint":false},{"pmid":"7803480","id":"PMC_7803480","title":"Purification and characterization of eukaryotic translational initiation factor eIF-2B from liver.","date":"1994","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/7803480","citation_count":56,"is_preprint":false},{"pmid":"15136689","id":"PMC_15136689","title":"Arg113His mutation in eIF2Bepsilon as cause of leukoencephalopathy in adults.","date":"2004","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15136689","citation_count":55,"is_preprint":false},{"pmid":"8164676","id":"PMC_8164676","title":"Mutations in the GCD7 subunit of yeast guanine nucleotide exchange factor eIF-2B overcome the inhibitory effects of phosphorylated eIF-2 on translation initiation.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8164676","citation_count":52,"is_preprint":false},{"pmid":"8168527","id":"PMC_8168527","title":"Use of monoclonal antibodies to study the structure and function of eukaryotic protein synthesis initiation factor eIF-2B.","date":"1994","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8168527","citation_count":48,"is_preprint":false},{"pmid":"15136690","id":"PMC_15136690","title":"Adult-onset leukoencephalopathy with vanishing white matter with a missense mutation in EIF2B5.","date":"2004","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15136690","citation_count":46,"is_preprint":false},{"pmid":"8007958","id":"PMC_8007958","title":"Expression of mutant eukaryotic initiation factor 2 alpha subunit (eIF-2 alpha) reduces inhibition of guanine nucleotide exchange activity of eIF-2B mediated by eIF-2 alpha phosphorylation.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8007958","citation_count":41,"is_preprint":false},{"pmid":"28961236","id":"PMC_28961236","title":"Transcriptome analysis of hypoxic cancer cells uncovers intron retention in EIF2B5 as a mechanism to inhibit translation.","date":"2017","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/28961236","citation_count":40,"is_preprint":false},{"pmid":"12133000","id":"PMC_12133000","title":"Evidence that the dephosphorylation of Ser(535) in the epsilon-subunit of eukaryotic initiation factor (eIF) 2B is insufficient for the activation of eIF2B by insulin.","date":"2002","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12133000","citation_count":40,"is_preprint":false},{"pmid":"3646234","id":"PMC_3646234","title":"Evidence that phosphorylation of eIF-2(alpha) prevents the eIF-2B-mediated dissociation of eIF-2 X GDP from the 60 S subunit of complete initiation complexes.","date":"1987","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3646234","citation_count":35,"is_preprint":false},{"pmid":"2842334","id":"PMC_2842334","title":"Regulation of protein synthesis in rabbit reticulocyte lysate. Glucose 6-phosphate is required to maintain the activity of eukaryotic initiation factor (eIF)-2B by a mechanism that is independent of the phosphorylation of eIF-2 alpha.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2842334","citation_count":33,"is_preprint":false},{"pmid":"6088496","id":"PMC_6088496","title":"The association of eIF-2 with Met-tRNAi or eIF-2B alters the specificity of eIF-2 phosphatase.","date":"1984","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6088496","citation_count":25,"is_preprint":false},{"pmid":"19950192","id":"PMC_19950192","title":"Epigenetic control of translation regulation: alterations in histone H3 lysine 9 post-translation modifications are correlated with the expression of the translation initiation factor 2B (Eif2b5) during thermal control establishment.","date":"2010","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19950192","citation_count":24,"is_preprint":false},{"pmid":"36100884","id":"PMC_36100884","title":"LncRNA KCNQ1OT1 promotes the metastasis of ovarian cancer by increasing the methylation of EIF2B5 promoter.","date":"2022","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/36100884","citation_count":23,"is_preprint":false},{"pmid":"12376332","id":"PMC_12376332","title":"Phosphorylation of eukaryotic initiation factor eIF2Bepsilon in skeletal muscle during sepsis.","date":"2002","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12376332","citation_count":23,"is_preprint":false},{"pmid":"33300869","id":"PMC_33300869","title":"Vanishing white matter disease expression of truncated EIF2B5 activates induced stress response.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33300869","citation_count":21,"is_preprint":false},{"pmid":"10913625","id":"PMC_10913625","title":"The activation of eukaryotic initiation factor (eIF)2B by growth factors in PC12 cells requires MEK/ERK signalling.","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10913625","citation_count":20,"is_preprint":false},{"pmid":"31587290","id":"PMC_31587290","title":"Glial pathology in a novel spontaneous mutant mouse of the Eif2b5 gene: a vanishing white matter disease model.","date":"2019","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31587290","citation_count":19,"is_preprint":false},{"pmid":"8368492","id":"PMC_8368492","title":"Preparation of a cell-free translation system with minimal loss of initiation factor eIF-2/eIF-2B activity.","date":"1993","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8368492","citation_count":17,"is_preprint":false},{"pmid":"7616232","id":"PMC_7616232","title":"Purification and characterization of guanine nucleotide-exchange factor, eIF-2B, and p37 calmodulin-binding protein from calf brain.","date":"1995","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7616232","citation_count":17,"is_preprint":false},{"pmid":"24023715","id":"PMC_24023715","title":"DYRK2 negatively regulates cardiomyocyte growth by mediating repressor function of GSK-3β on eIF2Bε.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24023715","citation_count":16,"is_preprint":false},{"pmid":"22238343","id":"PMC_22238343","title":"Identification of intersubunit domain interactions within eukaryotic initiation factor (eIF) 2B, the nucleotide exchange factor for translation initiation.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22238343","citation_count":16,"is_preprint":false},{"pmid":"16864840","id":"PMC_16864840","title":"Peripheral neuropathy in vanishing white matter disease with a novel EIF2B5 mutation.","date":"2006","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16864840","citation_count":15,"is_preprint":false},{"pmid":"20484009","id":"PMC_20484009","title":"Ectopic expression of eIF2Bepsilon in rat skeletal muscle rescues the sepsis-induced reduction in guanine nucleotide exchange activity and protein synthesis.","date":"2010","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20484009","citation_count":14,"is_preprint":false},{"pmid":"26285592","id":"PMC_26285592","title":"Biochemical effects of mutations in the gene encoding the alpha subunit of eukaryotic initiation factor (eIF) 2B associated with Vanishing White Matter disease.","date":"2015","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26285592","citation_count":14,"is_preprint":false},{"pmid":"1764100","id":"PMC_1764100","title":"The conversion of eIF-2.GDP to eIF-2.GTP by eIF-2B requires Met-tRNA(fMet).","date":"1991","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1764100","citation_count":14,"is_preprint":false},{"pmid":"3844338","id":"PMC_3844338","title":"Evaluation and significance of kinetic parameters governing function of protein synthesis initiation factors eIF-2 and eIF-2B.","date":"1985","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/3844338","citation_count":13,"is_preprint":false},{"pmid":"35710311","id":"PMC_35710311","title":"CircAHNAK upregulates EIF2B5 expression to inhibit the progression of ovarian cancer by modulating the JAK2/STAT3 signaling pathway.","date":"2022","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/35710311","citation_count":12,"is_preprint":false},{"pmid":"29491431","id":"PMC_29491431","title":"Adult mouse eIF2Bε Arg191His astrocytes display a normal integrated stress response in vitro.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29491431","citation_count":12,"is_preprint":false},{"pmid":"23335982","id":"PMC_23335982","title":"A yeast purification system for human translation initiation factors eIF2 and eIF2Bε and their use in the diagnosis of CACH/VWM disease.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23335982","citation_count":12,"is_preprint":false},{"pmid":"3435553","id":"PMC_3435553","title":"Kinetic constants in the functioning of eIF-2 and eIF-2B.","date":"1987","source":"Biochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/3435553","citation_count":12,"is_preprint":false},{"pmid":"27651498","id":"PMC_27651498","title":"Ovarioleukodystrophy due to EIF2B5 mutations.","date":"2016","source":"Practical neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27651498","citation_count":11,"is_preprint":false},{"pmid":"7753796","id":"PMC_7753796","title":"Molecular cloning and characterization of cDNA encoding the alpha subunit of the rat protein synthesis initiation factor eIF-2B.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7753796","citation_count":11,"is_preprint":false},{"pmid":"7802867","id":"PMC_7802867","title":"Protein synthesis in the developing rat liver: participation of initiation factors eIF-2 and eIF-2B.","date":"1994","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/7802867","citation_count":10,"is_preprint":false},{"pmid":"18294360","id":"PMC_18294360","title":"Exon deletion in the non-catalytic domain of eIF2Bepsilon due to a splice site mutation leads to infantile forms of CACH/VWM with severe decrease of eIF2B GEF activity.","date":"2008","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18294360","citation_count":9,"is_preprint":false},{"pmid":"6498200","id":"PMC_6498200","title":"Translation in micrococcal nuclease-treated cell-free extracts from Ehrlich ascites tumor cells. Stimulation by initiation factor eIF-2B.","date":"1984","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/6498200","citation_count":9,"is_preprint":false},{"pmid":"7982969","id":"PMC_7982969","title":"The delta-subunit of murine guanine nucleotide exchange factor eIF-2B. Characterization of cDNAs predicts isoforms differing at the amino-terminal end.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7982969","citation_count":8,"is_preprint":false},{"pmid":"9345299","id":"PMC_9345299","title":"Catalysis of guanine nucleotide exchange on eIF-2 by eIF-2B: is it a sequential or substituted enzyme mechanism?","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9345299","citation_count":8,"is_preprint":false},{"pmid":"23124037","id":"PMC_23124037","title":"Identification of MRI1, encoding translation initiation factor eIF-2B subunit alpha/beta/delta-like protein, as a candidate locus for infantile epilepsy with severe cystic degeneration of the brain.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23124037","citation_count":7,"is_preprint":false},{"pmid":"9236156","id":"PMC_9236156","title":"The effects of pyrroloquinoline quinone on heme-regulated eIF-2alpha kinase and eIF-2B activities in eukaryotic protein synthesis.","date":"1997","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/9236156","citation_count":7,"is_preprint":false},{"pmid":"26671108","id":"PMC_26671108","title":"No evidence for a role of Ile587Val polymorphism of EIF2B5 gene in multiple sclerosis in Kashmir Valley of India.","date":"2015","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26671108","citation_count":6,"is_preprint":false},{"pmid":"3647910","id":"PMC_3647910","title":"eIF-2B and the exchange of guanine nucleotides bound to eIF-2.","date":"1987","source":"The International journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3647910","citation_count":6,"is_preprint":false},{"pmid":"38454603","id":"PMC_38454603","title":"In vivo base editing of a pathogenic Eif2b5 variant improves vanishing white matter phenotypes in mice.","date":"2024","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38454603","citation_count":5,"is_preprint":false},{"pmid":"33245593","id":"PMC_33245593","title":"A novel hypomorphic splice variant in EIF2B5 gene is associated with mild ovarioleukodystrophy.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33245593","citation_count":5,"is_preprint":false},{"pmid":"25758335","id":"PMC_25758335","title":"Infantile onset Vanishing White Matter disease associated with a novel EIF2B5 variant, remarkably long life span, severe epilepsy, and hypopituitarism.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25758335","citation_count":5,"is_preprint":false},{"pmid":"22699478","id":"PMC_22699478","title":"Ovarioleukodystrophy: report of a case with the c.338G>A (p.Arg113His) mutation on exon 3 and the c.896G>A (p.Arg299His) mutation on exon 7 of the EIF2B5 gene.","date":"2011","source":"BMJ case reports","url":"https://pubmed.ncbi.nlm.nih.gov/22699478","citation_count":5,"is_preprint":false},{"pmid":"28093708","id":"PMC_28093708","title":"Multiple Sclerosis and EIF2B5: A Paradox or a Missing Link.","date":"2017","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/28093708","citation_count":4,"is_preprint":false},{"pmid":"24980014","id":"PMC_24980014","title":"Novel mutations identified in EIF2B5 gene in Kashmiri patients as susceptibility factor for multiple sclerosis.","date":"2014","source":"Indian journal of biochemistry & biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/24980014","citation_count":3,"is_preprint":false},{"pmid":"29933199","id":"PMC_29933199","title":"Vanishing white matter disease with a novel EIF2B5 mutation: A 10-year follow-up.","date":"2018","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/29933199","citation_count":3,"is_preprint":false},{"pmid":"25230711","id":"PMC_25230711","title":"Vanishing white matter disease with mutations in EIF2B5 gene.","date":"2014","source":"Indian journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/25230711","citation_count":3,"is_preprint":false},{"pmid":"35785335","id":"PMC_35785335","title":"Association Between Late-Onset Leukoencephalopathy With Vanishing White Matter and Compound Heterozygous EIF2B5 Gene Mutations: A Case Report and Review of the Literature.","date":"2022","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35785335","citation_count":3,"is_preprint":false},{"pmid":"29382480","id":"PMC_29382480","title":"[Association between homozygous c.318A>GT mutation in exon 2 of the EIF2B5 gene and the infantile form of vanishing white matter leukoencephalopathy].","date":"2017","source":"Boletin medico del Hospital Infantil de Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/29382480","citation_count":3,"is_preprint":false},{"pmid":"8103216","id":"PMC_8103216","title":"Purification of eukaryotic initiation factors eIF-2, eIF-2B and eIF-2 alpha kinase from bovine liver.","date":"1993","source":"Preparative biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8103216","citation_count":3,"is_preprint":false},{"pmid":"34399164","id":"PMC_34399164","title":"Translation initiation factor eIF2Bε promotes Wnt-mediated clonogenicity and global translation in intestinal epithelial cells.","date":"2021","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34399164","citation_count":2,"is_preprint":false},{"pmid":"40326783","id":"PMC_40326783","title":"Cell-specific Eif2b5 mutant mice: novel insights into roles of macroglia in vanishing white matter.","date":"2025","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40326783","citation_count":2,"is_preprint":false},{"pmid":"40246131","id":"PMC_40246131","title":"EIF2B5 promotes malignant progression of hepatocellular carcinoma by activating the PI3K/AKT signaling pathway through targeting RPL6.","date":"2025","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/40246131","citation_count":1,"is_preprint":false},{"pmid":"37674283","id":"PMC_37674283","title":"A novel missense variant in EIF2B5 identified in a consanguineous Iranian family with vanishing white matter disease and a brief review of the literature.","date":"2023","source":"Journal of genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37674283","citation_count":0,"is_preprint":false},{"pmid":"41700296","id":"PMC_41700296","title":"Adult-onset vanishing white matter disease caused by the EIF2B5 c.185A>T (p.Asp62Val) variant.","date":"2026","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41700296","citation_count":0,"is_preprint":false},{"pmid":"38829246","id":"PMC_38829246","title":"[Vanishing white matter disease, a rare leukodystrophy with mutation in the EIF2B5 gene].","date":"2024","source":"Ideggyogyaszati szemle","url":"https://pubmed.ncbi.nlm.nih.gov/38829246","citation_count":0,"is_preprint":false},{"pmid":"41244982","id":"PMC_41244982","title":"\"Case report\": Whole-exome sequencing reveals compound heterozygous variants in the EIF2B5 gene in a familial case of vanishing white matter.","date":"2025","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41244982","citation_count":0,"is_preprint":false},{"pmid":"7866313","id":"PMC_7866313","title":"Is there a need for channelling in the functioning of the protein synthesis initiation factors eIF-2 and eIF-2B?","date":"1994","source":"Biochemistry and molecular biology international","url":"https://pubmed.ncbi.nlm.nih.gov/7866313","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.01.14.633074","title":"The Translational Landscape of Reactive Astrocytes Reveals the Impact of eIF2B-mediated Dysregulation in VWM Disease","date":"2025-01-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.14.633074","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.29.626040","title":"Epigenetic study of the long-term effects of Gulf War illness","date":"2024-12-03","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.29.626040","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":34685,"output_tokens":7467,"usd":0.10803},"stage2":{"model":"claude-opus-4-6","input_tokens":11476,"output_tokens":4617,"usd":0.259207},"total_usd":0.367237,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Glycogen synthase kinase-3 (GSK-3) phosphorylates the epsilon subunit of eIF-2B, and insulin rapidly inactivates GSK-3 (via phosphorylation of GSK-3 itself, reversible by protein phosphatase-2A), thereby modulating eIF-2B activity.\",\n      \"method\": \"Chromatographic fractionation of CHO cell extracts, kinase assays with GSK-3-specific peptide substrates, immunoblotting with isoform-specific GSK-3 antibodies, phosphatase treatment\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay plus immunoblotting; replicated and foundational; consistent with multiple downstream studies\",\n      \"pmids\": [\"8397507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"eIF-2B is the guanine nucleotide exchange factor (GEF) for eIF-2; it promotes release of GDP from inactive eIF-2·GDP complexes to allow formation of active eIF-2·GTP, and this activity is inhibited when the alpha subunit of eIF-2 is phosphorylated. eIF-2B is a heteropentamer (subunits α, β, γ, δ, ε); the ε subunit is the catalytic subunit phosphorylated by protein kinases in liver extracts.\",\n      \"method\": \"Purification of eIF-2B from rat/bovine liver to >95% homogeneity; guanine nucleotide exchange assays; monoclonal antibody generation; protein kinase assays on individual subunits\",\n      \"journal\": \"Biochimica et biophysica acta / Biochimie / European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution, biochemical purification, in vitro enzymatic assay; replicated across multiple labs\",\n      \"pmids\": [\"7803480\", \"7893825\", \"8168527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Phosphorylation of eIF-2α at Ser-51 by eIF-2α kinase (HRI) inhibits eIF-2B guanine nucleotide exchange activity in cell extracts; Ser-48 of eIF-2α also contributes by maintaining high-affinity interaction between phosphorylated eIF-2α and eIF-2B, sequestering eIF-2B in an inactive complex.\",\n      \"method\": \"Cell extracts from CHO cells overexpressing wild-type or mutant eIF-2α (S48A, S51A); in vitro kinase treatment with purified HRI; GEF activity assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis plus in vitro kinase assay, mechanistic follow-up with multiple mutants\",\n      \"pmids\": [\"8007958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Overexpression of all five subunits of eIF-2B suppresses the growth-inhibitory and translational effects of eIF-2α hyperphosphorylation in yeast, establishing that phosphorylated eIF-2 acts as a competitive inhibitor of eIF-2B (rather than forming an irreversible inhibitory complex), and that eIF-2·GTP·Met-tRNA ternary complex concentration is the cardinal parameter controlling translation.\",\n      \"method\": \"Yeast genetic overexpression of eIF-2B subunits (all five), gene dosage experiments, GCN4-lacZ reporter assays, genetic epistasis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple orthogonal readouts; foundational yeast study directly applicable to mammalian eIF2B5 function\",\n      \"pmids\": [\"7565788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Mutations in the GCD7 (β) and GCD2 (δ) subunits of yeast eIF-2B suppress inhibition by phosphorylated eIF-2α, revealing that these subunits mediate the regulatory interaction between phospho-eIF-2 and eIF-2B without impairing the essential catalytic function, and that the eIF-2B complex can be rendered insensitive to eIF-2α phosphorylation.\",\n      \"method\": \"Yeast suppressor screen; GCN4-lacZ reporter; in vivo phosphorylation assays; growth assays with activated GCN2c kinase\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with suppressor screen, multiple mutant alleles, replicated in yeast ortholog studies\",\n      \"pmids\": [\"8164676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The C-terminal domain of eIF2Bε (residues 518–712 in yeast) is required for both catalytic GEF activity and binding to eIF-2; the N-terminal half of eIF2Bε contains an activation domain that responds to complex formation with other eIF2B subunits to enhance the nucleotide exchange rate, but missense mutations in this domain impair complex-stimulated activity without affecting intrinsic exchange activity or eIF2 binding.\",\n      \"method\": \"Yeast mutagenesis (nonsense, missense, in-frame deletions) of GCD6 (eIF2Bε); in vitro GEF assays with purified proteins; co-immunoprecipitation of subunit interactions\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — systematic mutagenesis combined with in vitro GEF assays and binding assays; comprehensive domain dissection\",\n      \"pmids\": [\"10805739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"DYRK2 and DYRK1A phosphorylate Ser-539 (rat numbering) in eIF2Bε, which is a priming phosphorylation that enables GSK-3 to subsequently phosphorylate the inhibitory Ser-535 site; eIF2Bε is highly phosphorylated at Ser-539 in vivo.\",\n      \"method\": \"In vitro kinase assays with purified DYRK isoforms, GSK-3, and eIF2Bε peptides/protein; mass spectrometry of phosphorylation sites; in vivo phosphorylation analysis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of sequential phosphorylation; site-specific identification; confirmed in vivo\",\n      \"pmids\": [\"11311121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"GSK-3 phosphorylates Ser-535 of eIF2Bε in vivo (confirmed by GSK-3 inhibitors LiCl, SB-415286, SB-216763 causing dephosphorylation), but dephosphorylation of Ser-535 alone is insufficient to activate eIF-2B in response to insulin, indicating that additional regulatory inputs are required for eIF2B activation.\",\n      \"method\": \"Pharmacological GSK-3 inhibitors in CHO cells; phospho-specific antibodies against Ser-535; eIF2B activity assays; phosphoinositide 3-kinase pathway inhibitors\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal pharmacological tools with kinase activity and phosphorylation readouts in the same study\",\n      \"pmids\": [\"12133000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Agents that disrupt ER Ca2+ homeostasis (thapsigargin, A23187, EGTA, DTT) inhibit translational initiation in GH3 cells concomitantly with ~5-fold increase in eIF-2α phosphorylation and ~50% reduction in eIF-2B activity, establishing that ER stress leads to eIF-2B inhibition via eIF-2α phosphorylation.\",\n      \"method\": \"Metabolic labeling, isoelectric focusing of eIF-2α, eIF-2B activity assays, acute and chronic drug treatment in intact cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (phosphorylation + activity assays) with functional consequence; foundational ER stress-eIF2B link\",\n      \"pmids\": [\"1512215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Glucose activates eIF-2B activity in isolated rat pancreatic islets within 15 min via a pathway independent of changes in eIF-2α phosphorylation, indicating a direct regulatory mechanism for eIF-2B activity by glucose metabolism.\",\n      \"method\": \"Isolated rat islet preparations; guanine nucleotide exchange assays; isoelectric focusing of eIF-2α; non-metabolizable glucose analogue controls\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — biochemical activity assays with appropriate controls demonstrating phosphorylation-independent mechanism\",\n      \"pmids\": [\"8567668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Sepsis increases GSK-3 activity (reduced Ser-9 phosphorylation of GSK-3β) and augments phosphorylation of eIF2Bε-Ser-535 by >2-fold in rat skeletal muscle, reducing eIF2B activity; TNF-binding protein treatment prevented these changes, implicating TNF as the mediator. This provides the first in vivo demonstration of eIF2Bε phosphorylation changes.\",\n      \"method\": \"Rat sepsis model; phospho-specific antibodies; eIF2B kinase/phosphatase activity assays; in vivo pharmacological intervention with TNF-binding protein\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo model with multiple readouts (phosphorylation, kinase activity, pharmacological rescue); first in vivo demonstration\",\n      \"pmids\": [\"12376332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"EGF- and NGF-induced activation of eIF-2B in PC12 cells requires MEK/ERK signaling (blocked by PD98059), and this activation is accompanied by GSK-3 inactivation; however, activation of eIF-2B occurs without detectable change in Ser-535 phosphorylation of eIF2Bε, indicating MEK/ERK-dependent but GSK-3/Ser-535-independent regulatory mechanisms.\",\n      \"method\": \"PC12 cell pharmacological inhibition (PD98059); eIF-2B activity assays; phospho-specific antibody detection of Ser-535\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological epistasis with activity and phosphorylation readouts; single lab, single study\",\n      \"pmids\": [\"10913625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Resistance exercise in young men reduces phosphorylation of eIF2Bε at Ser-540 (equivalent to rat Ser-535) in skeletal muscle, consistent with GSK-3 inhibition and eIF-2B activation, linking exercise signaling to eIF2Bε dephosphorylation.\",\n      \"method\": \"Human skeletal muscle biopsies; phospho-specific immunoblotting; unilateral exercise design with contralateral control\",\n      \"journal\": \"American journal of physiology. Regulatory, integrative and comparative physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct phosphorylation measurement in vivo in humans; single study, single method for eIF2Bε\",\n      \"pmids\": [\"18565837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"EIF2B5 mutations in VWM patient cells severely compromise the generation of GFAP+ astrocytes from glial progenitors; RNAi targeting of EIF2B5 in normal human glial progenitors phenocopies this defect, establishing a specific cell-autonomous role for eIF2Bε in astrocyte differentiation.\",\n      \"method\": \"Primary cell culture from VWM patient brain; GFAP immunostaining; siRNA knockdown of EIF2B5 in normal human glial progenitors\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient-derived cells plus RNAi knockdown with defined cellular phenotype; two orthogonal approaches\",\n      \"pmids\": [\"15723074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"DYRK2 negatively regulates cardiomyocyte growth by priming GSK-3β-mediated phosphorylation and inhibition of eIF2Bε; DYRK2 overexpression increases p-Ser535-eIF2Bε and reduces cardiomyocyte size, while DYRK2 knockdown decreases p-Ser535-eIF2Bε; constitutively active eIF2Bε-S535A causes cardiac hypertrophy in transgenic mice.\",\n      \"method\": \"Transgenic mice overexpressing eIF2Bε or eIF2Bε-S535A; adenoviral overexpression of DYRK2 in cardiomyocytes; siRNA knockdown of DYRK2; phospho-specific immunoblotting; cardiac morphometry\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (transgenic, adenoviral OE, siRNA KD) with defined in vivo and cellular phenotypes\",\n      \"pmids\": [\"24023715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The pyrophosphorylase-like domain (PLD) and left-handed β-helix domain of eIF2Bε and eIF2Bγ mediate critical inter-subunit interactions required for eIF2B complex formation; no evidence supports the PLD of eIF2Bε contributing to nucleotide exchange activity directly.\",\n      \"method\": \"Yeast genetic analysis; co-expression and co-precipitation of deletion/domain constructs; predicted structural modeling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-precipitation plus genetic analysis; single lab study on domain interactions\",\n      \"pmids\": [\"22238343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The C-terminal domain of human eIF2Bε has GEF activity when expressed and purified from yeast; VWM disease mutations within this domain reduce its GEF activity, confirming that the catalytic domain of eIF2Bε is directly impaired by VWM mutations.\",\n      \"method\": \"Affinity purification of recombinant human eIF2Bε C-terminal domain from engineered yeast; in vitro GEF assays; comparison with patient lymphocyte-derived eIF2B activity\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of human eIF2Bε GEF activity; first demonstration of human domain activity; validated against patient mutations\",\n      \"pmids\": [\"23335982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"eIF2Bε acts as a downstream effector of the AKT-GSK-3β signaling axis in CNS axon regeneration; inactivation of eIF2Bε reduces GSK-3β and AKT-mediated axon regeneration of retinal ganglion cells after optic nerve injury, while constitutively active eIF2Bε is sufficient to promote axon regeneration independently of mTORC1.\",\n      \"method\": \"Mouse optic nerve injury model; conditional Pten deletion; genetic epistasis with constitutively active and dominant-negative eIF2Bε constructs; retinal ganglion cell survival and axon counting\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with loss-of-function and gain-of-function in vivo; defined cellular and molecular phenotype\",\n      \"pmids\": [\"26974342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Under hypoxia, intron retention in EIF2B5 generates a 65 kDa truncated eIF2Bε isoform that acts as a dominant-negative to inhibit global translation; this is mediated by hypoxia-induced SRSF3 binding at the retained intron and increased Ser2-phosphorylated RNA Pol II at this region during cotranscriptional processing.\",\n      \"method\": \"RNA-seq/exon-level analysis; minigene splicing assays; expression of truncated isoform in cancer cells; polysome profiling; RIP assays for SRSF3; ChIP for phospho-Pol II\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (RNA-seq, RIP, ChIP, functional overexpression) establishing mechanism in a single comprehensive study\",\n      \"pmids\": [\"28961236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ectopic expression of eIF2Bε in rat skeletal muscle increases GEF activity in healthy animals and rescues the sepsis-induced deficit in eIF2B GEF activity and muscle protein synthesis, demonstrating that eIF2Bε expression level is rate-limiting and sufficient to correct eIF2B deficits.\",\n      \"method\": \"In vivo plasmid transfection into tibialis anterior; sepsis rat model; GEF activity assays; protein synthesis measurement by metabolic labeling\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain-of-function with defined biochemical and physiological readout; rescue of disease phenotype\",\n      \"pmids\": [\"20484009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A point mutation in mouse Eif2b5 (p.Ile98Met) decreases eIF2B guanine nucleotide exchange activity on eIF2, elevates ATF4 (ER stress marker) in brain, causes white matter disruption with oligodendrocyte progenitor clustering, and produces neurological phenotypes including epileptic seizures and infertility, establishing direct links between eIF2Bε GEF function and CNS homeostasis.\",\n      \"method\": \"Spontaneous mutant mouse characterization; biochemical GEF assay; immunohistochemistry; GFAP and CHOP mRNA expression; behavioral testing\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with biochemical GEF assay validation and multiple orthogonal phenotypic readouts\",\n      \"pmids\": [\"31587290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In zebrafish VWM models, intron 12 retention in eif2b5 leads to a truncated eif2b5 transcript; expression of this truncated eif2b5 in wild-type larvae activates the integrated stress response (ISR) and impairs motor behavior, suggesting a feed-forward gain-of-function mechanism contributing to VWM pathophysiology.\",\n      \"method\": \"Zebrafish eif2b5 mutant generation; RNA analysis; rescue by human EIF2B2 expression; motor behavioral assays; ISR marker analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — zebrafish model with functional rescue and gain-of-function expression; single study\",\n      \"pmids\": [\"33300869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"eIF2Bε promotes Wnt-mediated clonogenicity and global translational capacity in intestinal epithelial cells; eIF2BεArg191His (reduced GEF activity) mice show impaired crypt formation, reduced stemness marker expression, and defective Paneth cell granule formation; eIF2Bε is essential for Wnt hyperactivation-associated translational increase in organoids.\",\n      \"method\": \"eIF2Bε Arg191His knock-in mice; intestinal organoid culture; GSK3β inhibitor Wnt activation; stemness marker expression; protein synthesis assays\",\n      \"journal\": \"Stem cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knock-in model with multiple cellular readouts; single lab\",\n      \"pmids\": [\"34399164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Cell-type-specific Eif2b5 conditional mouse models reveal that oligodendrocyte-specific Eif2b5 mutation is the primary driver of ataxia and myelination defects in VWM, while astrocyte-specific Eif2b5 mutation drives intramyelinic vacuolization and ATF4-related gene expression with only mild motor phenotype; neuronal Eif2b5 mutation produces very mild phenotype.\",\n      \"method\": \"Cell-type-specific conditional Eif2b5 mouse lines (astrocyte, oligodendrocyte, neuron Cre drivers); motor behavioral testing; neuropathology; IHC for myelin proteins, astrocyte/oligodendrocyte markers; ISR/ATF4 gene expression analysis\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — rigorous genetic epistasis with three distinct conditional lines and multiple orthogonal readouts establishing cell-type-specific contributions\",\n      \"pmids\": [\"40326783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Phosphorylation of eIF-2α prevents eIF-2B-mediated dissociation of eIF-2·GDP from the 60S ribosomal subunit of complete initiation complexes; exogenous eIF-2B restores this function in inhibited lysates, shifting complexes from half-mers back to actively elongating polysomes.\",\n      \"method\": \"Rabbit reticulocyte lysate; polysome fractionation; sucrose gradient sedimentation; addition of purified exogenous eIF-2B; Met-tRNA binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — biochemical reconstitution in lysate with defined functional readouts; single study\",\n      \"pmids\": [\"3646234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Purified eIF-2B requires Met-tRNA(fMet) to efficiently exchange GDP for GTP on eIF-2 under physiological conditions; tRNA(fMet) alone is ineffective, indicating that efficient recycling of eIF-2·GDP to eIF-2·GTP in vivo requires formation of the ternary Met-tRNA(fMet)·eIF-2·GTP complex to stabilize the product.\",\n      \"method\": \"In vitro GEF assays with purified eIF-2B, eIF-2, and tRNA components; comparison of GDP vs GTP exchange rates with/without Met-tRNA\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution with purified components; mechanistic insight; single study\",\n      \"pmids\": [\"1764100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A splice site mutation in EIF2B5 exon 6 causes exon skipping, deleting part of the non-catalytic N-terminal domain of eIF2Bε; the truncated protein is undetectable, and eIF2B GEF activity is severely decreased, demonstrating that the non-catalytic domain of eIF2Bε is required for complex formation and activity.\",\n      \"method\": \"RT-PCR analysis of patient lymphoblastoid cell RNA; GEF activity assay in patient cells; protein expression analysis\",\n      \"journal\": \"Annals of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — patient-derived cell biochemistry with GEF assay; single study\",\n      \"pmids\": [\"18294360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LncRNA KCNQ1OT1 recruits DNA methyltransferases (DNMT1, DNMT3A, DNMT3B) to the EIF2B5 promoter, increasing its methylation and suppressing EIF2B5 expression in ovarian cancer cells; EIF2B5 silencing rescues the anti-tumor effects of KCNQ1OT1 depletion.\",\n      \"method\": \"MS-PCR for EIF2B5 promoter methylation; RIP and ChIP assays for DNMT binding; dual luciferase reporter assay; siRNA knockdown rescue experiments\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — RIP, ChIP, and methylation assays; functional rescue; single lab study\",\n      \"pmids\": [\"36100884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"EIF2B5 directly interacts with ribosomal protein RPL6 (identified by mass spectrometry and co-immunoprecipitation) in hepatocellular carcinoma cells; EIF2B5 overexpression promotes RPL6 expression and activates the PI3K/AKT/mTOR pathway.\",\n      \"method\": \"Mass spectrometry after immunoprecipitation; co-IP validation; Western blotting; siRNA knockdown; mouse ectopic tumor assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP/MS identification in cancer context; no in vitro reconstitution or mechanistic dissection\",\n      \"pmids\": [\"40246131\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EIF2B5 (eIF2Bε) is the catalytic epsilon subunit of the heteropentameric guanine nucleotide exchange factor eIF2B, whose C-terminal domain mediates GDP-to-GTP exchange on eIF2, enabling formation of the eIF2·GTP·Met-tRNA ternary complex required for translation initiation; eIF2Bε activity is negatively regulated by sequential phosphorylation—first by DYRK1A/2 at Ser-539 (priming), then by GSK-3β at Ser-535 (inhibitory)—while phosphorylation of eIF-2α at Ser-51 by stress kinases (HRI, PKR, GCN2, PERK) causes phospho-eIF-2 to sequester and inhibit eIF2B; the N-terminal domain of eIF2Bε serves as an activation domain stimulated by assembly with the other four eIF2B subunits; insulin and growth factors relieve GSK-3β-mediated inhibition via PI3K/AKT, and MEK/ERK signaling provides additional phosphorylation-independent activation inputs; in the CNS, eIF2Bε dysfunction (as in VWM disease mutations) primarily compromises oligodendrocyte maturation and astrocyte function, disrupts the integrated stress response, and impairs white matter homeostasis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"EIF2B5 encodes the catalytic epsilon subunit of the heteropentameric guanine nucleotide exchange factor eIF2B, which recycles eIF2·GDP to eIF2·GTP to enable formation of the eIF2·GTP·Met-tRNAi ternary complex essential for translation initiation [PMID:7803480, PMID:8168527]. The C-terminal domain of eIF2Bε harbors intrinsic GEF activity and binds eIF2, while an N-terminal activation domain amplifies exchange activity upon assembly with the other four eIF2B subunits [PMID:10805739, PMID:23335982]. eIF2Bε is negatively regulated by sequential phosphorylation—DYRK1A/2 primes Ser-539, enabling GSK-3β to phosphorylate the inhibitory Ser-535 site—and is further inhibited when stress-kinase-phosphorylated eIF2α sequesters the holoenzyme; insulin/PI3K/AKT signaling relieves GSK-3β-mediated inhibition, while MEK/ERK provides a phosphorylation-independent activation input [PMID:8397507, PMID:11311121, PMID:12133000, PMID:10913625]. Biallelic EIF2B5 mutations cause vanishing white matter disease (VWM/CACH), with oligodendrocyte-specific loss of eIF2Bε GEF activity being the primary driver of myelination defects and ataxia, while astrocyte-specific dysfunction contributes to vacuolization and integrated stress response dysregulation [PMID:15723074, PMID:31587290, PMID:40326783].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Establishing that eIF-2B is the critical factor that reverses phospho-eIF2α-mediated translational inhibition by recycling eIF-2·GDP on ribosomes answered the question of how translational repression by eIF-2α kinases is mechanistically implemented.\",\n      \"evidence\": \"Rabbit reticulocyte lysate polysome fractionation with exogenous eIF-2B addition\",\n      \"pmids\": [\"3646234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single reconstitution system (reticulocyte lysate); subunit composition of active eIF-2B not determined\", \"Mechanism of phospho-eIF2α-mediated sequestration not resolved\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstrating that ER stress agents increase eIF-2α phosphorylation and reduce eIF-2B activity in intact cells established the first link between organellar stress and eIF-2B-dependent translational control.\",\n      \"evidence\": \"GH3 cell ER stress (thapsigargin/DTT); isoelectric focusing of eIF-2α; eIF-2B activity assays\",\n      \"pmids\": [\"1512215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the ER stress kinase (later identified as PERK) unknown at this time\", \"Whether eIF-2B subunit composition changes under stress not tested\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identifying GSK-3 as the kinase that phosphorylates eIF2Bε and showing insulin inactivates GSK-3 revealed a direct signaling axis from growth factors to translational control via eIF2B.\",\n      \"evidence\": \"Chromatographic fractionation of CHO cell extracts; kinase assays; GSK-3 isoform-specific immunoblotting\",\n      \"pmids\": [\"8397507\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact phosphorylation site on eIF2Bε not yet identified\", \"Whether GSK-3 requires a priming kinase not yet known\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Biochemical purification confirmed eIF-2B as a heteropentamer whose ε subunit is the catalytic component, while genetic epistasis in yeast showed phospho-eIF2α acts as a competitive inhibitor (not an irreversible poison) and that the β/δ subunits mediate the regulatory response to phospho-eIF2α.\",\n      \"evidence\": \"Purification from rat/bovine liver with GEF assays; yeast overexpression/suppressor genetics with GCN4-lacZ reporters; CHO cell eIF-2α mutagenesis with HRI kinase\",\n      \"pmids\": [\"7803480\", \"8168527\", \"7565788\", \"8164676\", \"8007958\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural information on the pentamer\", \"How ε cooperates with the regulatory subcomplexes not resolved at the protein level\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Glucose-stimulated eIF-2B activation in pancreatic islets independent of eIF-2α phosphorylation demonstrated that eIF2B activity is regulated by nutrient signals through mechanisms beyond the canonical phospho-eIF2α pathway.\",\n      \"evidence\": \"Isolated rat pancreatic islets; GEF assays; isoelectric focusing of eIF-2α\",\n      \"pmids\": [\"8567668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target on eIF2B for glucose signal unknown\", \"Whether eIF2Bε phosphorylation changes were not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Systematic mutagenesis of yeast eIF2Bε mapped catalytic GEF activity and eIF2 binding to the C-terminal domain and identified a distinct N-terminal activation domain responsive to holoenzyme assembly, establishing a two-domain architecture for eIF2Bε function.\",\n      \"evidence\": \"Yeast GCD6 mutagenesis (nonsense, missense, deletions); in vitro GEF assays; co-immunoprecipitation\",\n      \"pmids\": [\"10805739\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-resolution structure of either domain\", \"How N-terminal domain senses assembly not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"EGF/NGF activation of eIF-2B via MEK/ERK without changes in Ser-535 phosphorylation revealed a phosphorylation-independent regulatory input, indicating multiple convergent pathways control eIF2Bε.\",\n      \"evidence\": \"PC12 cell pharmacological inhibition (PD98059); eIF-2B activity assays; phospho-Ser535 immunoblotting\",\n      \"pmids\": [\"10913625\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Target of MEK/ERK on eIF2B not identified\", \"Single cell type and single lab\", \"Whether a distinct phosphorylation site is involved not excluded\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of DYRK1A/2 as the priming kinases for Ser-539 that enables GSK-3β to phosphorylate Ser-535 completed the sequential phosphorylation mechanism governing eIF2Bε inhibition.\",\n      \"evidence\": \"In vitro kinase assays with purified DYRKs, GSK-3, eIF2Bε peptides; mass spectrometry; in vivo phosphorylation analysis\",\n      \"pmids\": [\"11311121\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DYRK phosphorylation is itself regulated by signaling pathways not determined\", \"Phosphatase(s) that dephosphorylate these sites not identified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Pharmacological GSK-3 inhibition confirmed in vivo Ser-535 phosphorylation but showed it was insufficient for insulin-mediated eIF2B activation, proving that additional regulatory inputs exist beyond the GSK-3-Ser535 axis.\",\n      \"evidence\": \"CHO cells treated with GSK-3 inhibitors (LiCl, SB-415286, SB-216763); phospho-specific antibodies; eIF2B activity assays\",\n      \"pmids\": [\"12133000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the additional regulatory input(s) unknown\", \"Whether they converge on eIF2Bε or other subunits not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The first in vivo demonstration that sepsis increases eIF2Bε-Ser535 phosphorylation via TNF-mediated GSK-3 activation in skeletal muscle established pathological relevance of eIF2Bε phosphoregulation.\",\n      \"evidence\": \"Rat sepsis model; phospho-specific antibodies; eIF2B activity assays; TNF-binding protein rescue\",\n      \"pmids\": [\"12376332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TNF acts directly on muscle GSK-3 or via intermediary signaling not resolved\", \"Contribution of eIF-2α phosphorylation in sepsis not fully dissected\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that VWM patient-derived cells and EIF2B5-knockdown normal progenitors both fail to generate GFAP+ astrocytes established a cell-autonomous role for eIF2Bε in glial differentiation and connected EIF2B5 mutations to VWM disease pathology.\",\n      \"evidence\": \"Primary cultures from VWM patient brain; GFAP immunostaining; siRNA knockdown of EIF2B5 in normal human glial progenitors\",\n      \"pmids\": [\"15723074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking reduced GEF activity to astrocyte differentiation not identified\", \"Oligodendrocyte contribution not examined in this study\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Ectopic expression of eIF2Bε in rat skeletal muscle rescued sepsis-induced eIF2B GEF deficits and protein synthesis, showing that eIF2Bε expression level is rate-limiting for translation in catabolic states.\",\n      \"evidence\": \"In vivo plasmid transfection into rat tibialis anterior; sepsis model; GEF assays; metabolic labeling\",\n      \"pmids\": [\"20484009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether eIF2Bε stoichiometry with other subunits is maintained during overexpression not determined\", \"Long-term therapeutic potential not assessed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Mapping the pyrophosphorylase-like and left-handed β-helix domains as mediating eIF2Bε–eIF2Bγ inter-subunit contacts clarified the structural basis for holoenzyme assembly, distinct from the C-terminal catalytic domain.\",\n      \"evidence\": \"Yeast genetic analysis; co-expression/co-precipitation of domain constructs\",\n      \"pmids\": [\"22238343\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure available at this time\", \"Whether these domains contribute to regulation not tested\", \"Single lab study\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Purified human eIF2Bε C-terminal domain demonstrated GEF activity that was reduced by VWM mutations, directly linking patient genotypes to catalytic impairment; concurrently, DYRK2 was shown to regulate cardiomyocyte size through the DYRK2→GSK-3β→eIF2Bε-Ser535 axis, extending eIF2Bε phosphoregulation to cardiac hypertrophy.\",\n      \"evidence\": \"Recombinant human eIF2Bε catalytic domain purified from yeast with in vitro GEF assays; transgenic mice with eIF2Bε-S535A; adenoviral DYRK2 overexpression/knockdown in cardiomyocytes\",\n      \"pmids\": [\"23335982\", \"24023715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full holoenzyme reconstitution with VWM mutant subunits not achieved\", \"Whether cardiac hypertrophy phenotype involves ISR activation not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Constitutively active eIF2Bε promoted CNS axon regeneration downstream of AKT-GSK-3β and independently of mTORC1, revealing a new biological role for eIF2B-dependent translation in neural repair.\",\n      \"evidence\": \"Mouse optic nerve injury model; conditional Pten deletion with constitutively active or dominant-negative eIF2Bε constructs; axon counting\",\n      \"pmids\": [\"26974342\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which mRNAs are translationally upregulated by eIF2Bε in regenerating axons not identified\", \"Whether endogenous eIF2Bε is rate-limiting in the regeneration context not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Hypoxia-induced intron retention in EIF2B5 produces a dominant-negative truncated isoform that inhibits global translation, revealing a post-transcriptional layer of eIF2Bε regulation involving SRSF3-mediated cotranscriptional splicing.\",\n      \"evidence\": \"RNA-seq; minigene splicing assays; polysome profiling; RIP for SRSF3; ChIP for phospho-Pol II in cancer cells\",\n      \"pmids\": [\"28961236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological relevance of intron retention beyond cancer cell lines not established\", \"Whether this mechanism operates in normal tissue hypoxia (e.g., embryonic development) unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A spontaneous Eif2b5 point mutation in mice directly linked reduced GEF activity to white matter disruption, ATF4 elevation, epileptic seizures, and oligodendrocyte progenitor clustering, providing the first single-gene mouse model recapitulating VWM-like neuropathology.\",\n      \"evidence\": \"Spontaneous mouse mutant; biochemical GEF assay; immunohistochemistry; behavioral testing\",\n      \"pmids\": [\"31587290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ATF4 elevation is cause or consequence of pathology not resolved\", \"Mechanism of oligodendrocyte progenitor clustering unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"eIF2Bε GEF activity was shown to be required for Wnt-mediated intestinal stem cell clonogenicity and Paneth cell maturation, broadening eIF2Bε function beyond the CNS to epithelial homeostasis.\",\n      \"evidence\": \"eIF2Bε-R191H knock-in mice; intestinal organoid culture; Wnt activation by GSK3β inhibitor; stemness markers\",\n      \"pmids\": [\"34399164\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the phenotype is specific to eIF2Bε or general to eIF2B holoenzyme insufficiency not distinguished\", \"Translational targets downstream of Wnt-eIF2B axis not identified\", \"Single lab study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Cell-type-specific conditional Eif2b5 mutagenesis resolved a longstanding question by showing that oligodendrocyte-intrinsic eIF2Bε dysfunction is the primary driver of VWM motor phenotype and myelination defects, while astrocyte-intrinsic dysfunction drives vacuolization and ISR activation.\",\n      \"evidence\": \"Three conditional Eif2b5 mouse lines (oligodendrocyte, astrocyte, neuron Cre); motor behavior; neuropathology; ISR gene expression\",\n      \"pmids\": [\"40326783\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which reduced GEF activity specifically impairs oligodendrocyte maturation unknown\", \"Whether therapeutic GEF restoration in specific cell types is sufficient for rescue not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include: which specific mRNAs are translationally controlled by eIF2Bε activity changes in disease-relevant cell types; what phosphatases reverse Ser-535/Ser-539 phosphorylation; and what the complete structural basis is for VWM mutation-induced GEF impairment in the human holoenzyme context.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No translatome profiling of eIF2Bε-mutant cells in disease-relevant lineages\", \"Phosphatase(s) acting on eIF2Bε not identified\", \"Full structural impact of VWM mutations in assembled human decamer not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 5, 6, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 3, 5, 16, 24, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 7, 11, 17]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2, 8, 20]}\n    ],\n    \"complexes\": [\n      \"eIF2B\"\n    ],\n    \"partners\": [\n      \"EIF2S1\",\n      \"EIF2B1\",\n      \"EIF2B2\",\n      \"EIF2B3\",\n      \"EIF2B4\",\n      \"GSK3B\",\n      \"DYRK2\",\n      \"DYRK1A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}